" class="no-js "lang="en-US"> MilliporeSigma - Medtech Alert
Friday, August 01, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
MilliporeSigma | Pharmtech Focus

MilliporeSigma

About MilliporeSigma

MilliporeSigma

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

Related Story

Drug Development

 MilliporeSigma Invests $286 Million in U.S. Drug Safety Testing Capacity | PTF

MilliporeSigma Invests $286 Million in U.S. Drug Safety Testing Capacity

November 23 2022

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science […]

Industry News

 MilliporeSigma Announces Acquisition of MAST® Platform from Lonza

MilliporeSigma Announces Acquisition of MAST® Platform from Lonza, a Leading Automated Bioreactor Sampling System to Advance BioProcessing Capabilities

April 6 2022

MilliporeSigma, the U.S. and Canada life science business of Merck KGaA, Darmstadt, Germany a leading science and technology company, […]